Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neuroscience -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (57)	9/25/2000 12:40:00 PM
From: nigel bates	Respond to of 278

Point taken; but plus 15% represents qualified excitement, surely. (Setting to one side what one feels about the absolute valuation...) nig

To: scott_jiminez who wrote (57)	9/25/2000 10:40:02 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 278

<<While win/win may be the case, there remain few patients treated thus far with iloperidone, few published studies on the drug, and few direct comparisons to other atypical antopsychotics (clozapine, iloperidone, quetiapine, olanzapine, risperidone, ziprasidone etc.). >> ...few patients treated thus far...???? Two 600 pts pivotal placebo and active drug controlled completed. Highly statistical significant, positive and negative symptoms, no safety issue! GO FIGURE! Enrolment completed in third pivotal 600 pts as well as three +400 pts long-term studies! GO FIGURE! Did anyone done direct comparison for new atypical psychotic drug? GO FIGURE! Message 14453817 So, Mr SVEZNAJUCI, why You don't tell as more about? <<Larger and more inclusive trials will be required to fully support any excitement today's news engenders.>> Right! In your dream! Keep baying ARIA, so I can short it again. :) Cheers! Miljenko Son of Rick "neuro"